Effects of linagliptin versus voglibose on treatment-relatedquality of life in patients with type 2 diabetes: sub-analysis of the L-STEPstudy

Endocrine journal

Tomoya Mita¹  Masahiko Gosho²  Shimpei Fujimoto³  Masumi Ai⁴  Hiromasa Goto⁵  Hiroaki Satoh⁶  Toru Hiyoshi⁷  Takahisa Hirose⁸  Yosuke Okada⁹  Hisamoto Kuroda^1,10  Hideki Nishimura^1,11  Yoshio Fujitani^1,12  Toshiki Matsubara^1,13  Kiyohito Takahashi^1,14 

[1] Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan;Department of Clinical Trial and Clinical Epidemiology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan;Department of Endocrinology, Metabolism and Nephrology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan;Department of Insured Medical Care Management, Tokyo Medical and Dental University (TMDU), Tokyo, Japan;Department of Metabolism &Department of Nephrology, Hypertension, Diabetology, Endocrinology, and Metabolism, Fukushima Medical University, Fukushima, Japan;Division of Diabetes and Endocrinology, Department of Internal Medicine, Japanese Red Cross Medical Center, Tokyo, Japan;Division of Diabetes, Metabolism, and Endocrinology, Department of Medicine, Toho University School of Medicine, Tokyo, Japan;First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan;Green Clinic, Mibu, Tochigi, Japan;Kumanomae Nishimura Medical Clinic, Tokyo, Japan;Laboratory of Developmental Biology and Metabolism, Institute for Molecular and Cellular Regulation, Gunma University, Maebashi, Japan;Matsubara Clinic, Ichinomiya, Aichi, Japan;Takahashi Kiyohito Clinic, Hakodate, Hokkaido, Japan

关键词: Dipeptidyl peptidase-4 inhibitor;    Alpha-glucosidase inhibitor;    Treatment-related quality of life;    Type 2 diabetes mellitus;   

DOI  :  10.1507/endocrj.EJ18-0088

学科分类：内分泌与代谢学

来源: Japan Endocrine Society

【 摘 要 】

Treatment-related quality of life (QOL) is an important aspect of diabetes management. However, no studies have compared the influence of dipeptidyl peptidase-4 inhibitors versus alpha-glucosidase inhibitors on treatment-related QOL. This prespecified sub-analysis of the Linagliptin Study of Effects on Postprandial blood glucose (L-STEP) compared the effects of linagliptin (5 mg once daily) and voglibose (0.2 mg/meal thrice daily) on treatment-related QOL in Japanese patients with type 2 diabetes (T2DM) inadequately controlled with diet and exercise therapy. Among 366 subjects in the original study, 182 in the linagliptin group and 173 in the voglibose group were included in this analysis. The outcome of this study was change in QOL as assessed by the Diabetes Therapy-Related Quality of Life 17 (DTR-QOL17) questionnaire from baseline to week 12. Compared with baseline data, total DTR-QOL17 scores were significantly higher after 12 weeks of linagliptin and voglibose treatment. The change in the total DTR-QOL17 score and the score of one domain, burden on social activities and daily activities, was significantly greater in the linagliptin group than in the voglibose group. In addition, only linagliptin treatment was identified as a factor associated with an increased total DTR-QOL17 score. Linagliptin is superior to voglibose in terms of improving treatment-related QOL in Japanese patients with T2DM.

【 授权许可】

Unknown